MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease
Jin Wang,Jinyun Chen,Ping Chang,Aimee Leblanc,Donghui Li,James L. Abbruzzesse,Marsha L. Frazier,Ann M. Killary,Subrata Sen +8 more
Reads0
Chats0
TLDR
Observations show the feasibility of developing plasma miRNA profiling as a sensitive and specific blood-based biomarker assay for pancreatic cancer that has the potential of translation to the clinic with additional improvements in the future.Abstract:
Development of minimally invasive biomarker assays for early detection and effective clinical management of pancreatic cancer is urgently needed to reduce high morbidity and mortality associated with this malignancy We hypothesized that if aberrantly expressing microRNAs (miRNA) in pancreatic adenocarcinoma tissues are detected in blood plasma, then plasma profiling of these miRNAs might serve as a minimally invasive early detection biomarker assay for this malignancy By using a modified protocol to isolate and quantify plasma miRNAs from heparin-treated blood, we show that miRNA profiling in plasma can differentiate pancreatic adenocarcinoma patients from healthy controls We have profiled four miRNAs, miR-21, miR-210, miR-155, and miR-196a, all implicated in the development of pancreatic cancer with either proven or predicted target genes involved in critical cancer-associated cellular pathways Of these, miR-155 has recently been identified as a candidate biomarker of early pancreatic neoplasia, whereas elevated expression of miR196a has been shown to parallel progression of disease The results revealed a sensitivity of 64% and a specificity of 89% with the analyses of plasma levels for this panel of four miRNAs The area under the receiver operating characteristic curve were estimated at 082 and 078 without and with leave-one-out cross-validation scheme, respectively These observations, although a "proof of principle" finding at this time, show the feasibility of developing plasma miRNA profiling as a sensitive and specific blood-based biomarker assay for pancreatic cancer that has the potential of translation to the clinic with additional improvements in the futureread more
Citations
More filters
Journal ArticleDOI
MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells
TL;DR: Investigation of the potential role of microRNA-183-5p in the proliferation, invasion and metastasis of pancreatic cancer, and to identify promising target genes of oncogenic miR-183 -5p suggest it may be useful as a pancreatic cancers biomarker.
Journal ArticleDOI
Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.
Yantian Fang,Qizhi Yao,Zongyou Chen,Jianbin Xiang,Fisher E. William,Richard A. Gibbs,Changyi Chen +6 more
TL;DR: This review aims to summarize recent advances of important genes, proteins, and microRNAs that play a critical role in the pathogenesis of pancreatic cancer, and to provide implications for personalized medicine in Pancreas cancer.
Journal ArticleDOI
Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.
TL;DR: A panel of miRNAs with miR-146a, mi-222 and mi-223 could be used as potential noninvasive biomarkers for early detection of AD.
Journal ArticleDOI
Molecular markers in pancreatic cancer diagnosis
TL;DR: It is kept the hope that a combination of some of these novel biomarkers can be a useful tool for early PDAC diagnosis before image techniques and/or patient's symptoms reveal disease in an incurable state.
Journal ArticleDOI
Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia
Elena Vila-Navarro,Saray Duran-Sanchon,Maria Vila-Casadesús,Leticia Moreira,Angels Ginès,Miriam Cuatrecasas,Juan José Lozano,Luis Bujanda,Antoni Castells,Meritxell Gironella +9 more
TL;DR: Novel signatures combining miRNAs and CA19.9 could be used as noninvasive biomarkers for early detection of PDAC.
References
More filters
Journal ArticleDOI
Analyzing real-time PCR data by the comparative C(T) method.
TL;DR: This protocol provides an overview of the comparative CT method for quantitative gene expression studies and various examples to present quantitative gene Expression data using this method.
Journal ArticleDOI
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
TL;DR: It is shown here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity and established the measurement of tumor-derived mi RNAs in serum or plasma as an important approach for the blood-based detection of human cancer.
Journal ArticleDOI
A microRNA expression signature of human solid tumors defines cancer gene targets
Stefano Volinia,George A. Calin,Chang Gong Liu,Stefan Ambs,Amelia Cimmino,Fabio Petrocca,Rosa Visone,Marilena V. Iorio,Claudia Roldo,Manuela Ferracin,Robyn L. Prueitt,Nozumu Yanaihara,Giovanni Lanza,Aldo Scarpa,Andrea Vecchione,Massimo Negrini,Curtis C. Harris,Carlo M. Croce +17 more
TL;DR: The results indicate that miRNAs are extensively involved in cancer pathogenesis of solid tumors and support their function as either dominant or recessive cancer genes.
Journal ArticleDOI
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
TL;DR: It is shown that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21, which may contribute to the malignant phenotype by blocking expression of critical apoptosis-related genes.
Related Papers (5)
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
Xi Chen,Yi Ba,Lijia Ma,Lijia Ma,Xing Cai,Yuan Yin,Kehui Wang,Jigang Guo,Yujing Zhang,Jiangning Chen,Xing Guo,Qibin Li,Qibin Li,Xiaoying Li,Wenjing Wang,Yan Zhang,Jin Wang,Xueyuan Jiang,Yang Xiang,Chen Xu,Pingping Zheng,Juanbin Zhang,Ruiqiang Li,Hongjie Zhang,Xiaobin Shang,Ting Gong,Guang Ning,Jun Wang,Jun Wang,Ke Zen,Junfeng Zhang,Chen-Yu Zhang +31 more
MicroRNA expression profiles classify human cancers
Jun Lu,Gad Getz,Eric A. Miska,Eric A. Miska,Ezequiel Alvarez-Saavedra,Justin Lamb,David Peck,Alejandro Sweet-Cordero,Alejandro Sweet-Cordero,Benjamin L. Ebert,Benjamin L. Ebert,Raymond H. Mak,Raymond H. Mak,Adolfo A. Ferrando,James R. Downing,Tyler Jacks,H. Robert Horvitz,H. Robert Horvitz,Todd R. Golub,Todd R. Golub,Todd R. Golub +20 more